And divarasib reduced the risk for death by 44% during the trial, with a median overall survival (OS) of 17.7 versus 12 ...

ZURICH, Oct 25 (Reuters) - Swiss drugmaker Roche said on Sunday its experimental lung cancer drug divarasib reduced the risk ...

In a Phase 3 trial of previously treated KRAS G12C-mutated non-small cell lung cancer, Roche’s investigational drug divarasib ...

A drug from Amgen could give patients with an aggressive form of lung cancer significantly more time to live when added to an ...

Amgen (NASDAQ:AMGN) presented Phase III data at the European Society for Medical Oncology Congress 2026 showing that its DLL3-targeting BiTE therapy IMDELLTRA, when added to durvalumab maintenance ...

The investigational KRAS G12C inhibitor prolongs overall survival in previously treated advanced lung cancer vs existing ...

Bristol Myers Squibb reported that one patient died after receiving its investigational CAR-T therapy in an early autoimmune trial ...

AstraZeneca (AZN) said Saturday two phase 3 trials showed its cancer drug Imfinzi helped patients with extensive-stage small cell lung cancer and muscle-invasive bladder cancer, cutting the risk of ...

The drop in smoking rates in the United States and other countries has unexpectedly shed light on this as an emerging health issue ...

Amgen (NASDAQ:AMGN) today announced landmark interim Phase 3 results showing that IMDELLTRA® (tarlatamab-dlle) in combination with AstraZeneca's IMFINZI® (durvalumab) reduced the risk of death by 58% ...

Relapsed small-cell lung cancer has long been one of the most difficult malignancies to treat once platinum-based ...

Positive results from the SAFFRON Phase III trial showed TAGRISSO ® (osimertinib) plus savolitinib demonstrated a ...